Adenoviral gene therapy for bladder cancer

Roland W. Herzog; Masataka Suzuki

doi:10.1016/j.cell.2023.02.009

Adenoviral gene therapy for bladder cancer

Roland W. Herzog, Masataka Suzuki

Houston Methodist

Research output: Contribution to journal › Comment/debate › peer-review

7 Scopus citations

Abstract

Enhanced by polyamide surfactant Syn3, intravesical administration of rAd-IFNα2b results in transduction of the virus into the bladder epithelium, resulting in the synthesis and expression of local IFNα2b cytokine. Upon secretion, IFNα2b binds to the IFNα receptor on bladder cancer and other cells, resulting in signaling via the JAK-STAT pathway. A plethora of induced IFN-stimulated genes containing IFN-sensitive response elements that contribute to activation of pathways restrict cancer growth.

Original language	English (US)
Pages (from-to)	893
Number of pages	1
Journal	Cell
Volume	186
Issue number	5
DOIs	https://doi.org/10.1016/j.cell.2023.02.009
State	Published - Mar 2 2023

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.cell.2023.02.009

Cite this

@article{66a4745bcd8d412fbe29068e13eb4175,

title = "Adenoviral gene therapy for bladder cancer",

abstract = "Enhanced by polyamide surfactant Syn3, intravesical administration of rAd-IFNα2b results in transduction of the virus into the bladder epithelium, resulting in the synthesis and expression of local IFNα2b cytokine. Upon secretion, IFNα2b binds to the IFNα receptor on bladder cancer and other cells, resulting in signaling via the JAK-STAT pathway. A plethora of induced IFN-stimulated genes containing IFN-sensitive response elements that contribute to activation of pathways restrict cancer growth.",

author = "Herzog, \{Roland W.\} and Masataka Suzuki",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = mar,

day = "2",

doi = "10.1016/j.cell.2023.02.009",

language = "English (US)",

volume = "186",

pages = "893",

journal = "Cell",

issn = "0092-8674",

publisher = "Elsevier B.V.",

number = "5",

}

TY - JOUR

T1 - Adenoviral gene therapy for bladder cancer

AU - Herzog, Roland W.

AU - Suzuki, Masataka

PY - 2023/3/2

Y1 - 2023/3/2

N2 - Enhanced by polyamide surfactant Syn3, intravesical administration of rAd-IFNα2b results in transduction of the virus into the bladder epithelium, resulting in the synthesis and expression of local IFNα2b cytokine. Upon secretion, IFNα2b binds to the IFNα receptor on bladder cancer and other cells, resulting in signaling via the JAK-STAT pathway. A plethora of induced IFN-stimulated genes containing IFN-sensitive response elements that contribute to activation of pathways restrict cancer growth.

AB - Enhanced by polyamide surfactant Syn3, intravesical administration of rAd-IFNα2b results in transduction of the virus into the bladder epithelium, resulting in the synthesis and expression of local IFNα2b cytokine. Upon secretion, IFNα2b binds to the IFNα receptor on bladder cancer and other cells, resulting in signaling via the JAK-STAT pathway. A plethora of induced IFN-stimulated genes containing IFN-sensitive response elements that contribute to activation of pathways restrict cancer growth.

UR - https://www.scopus.com/pages/publications/85149073546

UR - https://www.scopus.com/inward/citedby.url?scp=85149073546&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2023.02.009

DO - 10.1016/j.cell.2023.02.009

M3 - Comment/debate

C2 - 36868210

AN - SCOPUS:85149073546

SN - 0092-8674

VL - 186

SP - 893

JO - Cell

JF - Cell

IS - 5

ER -

Adenoviral gene therapy for bladder cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this